Potek bolezni pri bolnicah s HER-2 pozitivnim rakom dojk
Clinical course of HER-2 positive breast cancer patients

Authors

  • Domen Ribnikar
  • Špela Fink
  • Snježana Frković-Grazio Onkološki inštitut, Ljubljana
  • Hotimir Lešničar Onkološki inštitut, Ljubljana
  • Aleksander Sadikov

Keywords:

HER-2 positive breast cancer, breast cancer

Abstract

Ni abstrakta.


Abstract (Eng)

Breast cancer is the most frequent cancer in women. The course and efficiency of breast cancer treatment are influenced by several factors. The expression of HER-2 protein and HER-2 gene is gaining in strength in breast cancer management. The aim of our study was to compare the course of HER-2 positive with HER-2 negative disease. In median time of 2.5 years DFS (disease-free-survival) of patients with HER-2 positive tumours was 76.1%, and 93.4% for patients with HER-2 negative disease. HER-2 status was the strongest prognostic factor for DFS (p<0.001) in the multivariate model, ranking before nodal status, PR status and age of patients. We may conclude that patients with HER-2 positive disease have worse survival regardless ofnodal status.

Downloads

Published

2008-12-15

How to Cite

Ribnikar, D., Fink, Špela, Frković-Grazio, S., Lešničar, H., & Sadikov, A. (2008). Clinical course of HER-2 positive breast cancer patients. Onkologija : Slovenian Journal of Oncology, 12(2), 94–98. Retrieved from https://revijaonkologija.si/Onkologija/article/view/393

Issue

Vol. 12 No. 2 (2008)

Section

Original Scientific Article

License

The journal is published under the terms of the Creative Commons Attribution License CC-BY 4.0. The authors retain the copyright to their work without any restrictions whatsoever.

This journal is an open-access journal, meaning that all of its contents are freely accessible without any charge to the user or their institution. In accordance with the Budapest Open Access Initiative (BOAI) definition of open access, users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking for prior permission from the publisher or the author, provided the authors and the journal are appropriately credited.